The Absorption and Metabolism of Seaweed Polyphenols in Humans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Brown seaweeds are a rich source of phlorotannins, a characteristic class of polyphenols which are unique to seaweeds of this type and can comprise 5 to 15 % of the dried weight. Unlike other classes of polyphenols, there is a lack of knowledge regarding phlorotannins and their bioavailability and bioactivity. The purpose of this study is to investigate the absorption and metabolism of seaweed polyphenols in humans. As part of an EC project (SWAFAX), an acute clinical intervention will be conducted to investigate the metabolism/ bioavailability of brown seaweed phlorotannins. Urine and plasma samples from 24 healthy volunteers that consumed a seaweed capsule containing polyphenols will be collected before and after the intervention. Data emanating from this project will provide strong scientific evidence for bioavailability and health promoting activity of a seaweed polyphenol extract in human volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Seaweed Derived Polyphenols on Inflammation and Oxidative Stress in Vivo - The SWAFAX Study

NCT02295878

Cardiovascular Disease

COMPLETED NA

Effect of Polyphenol Extract on Cardiovascular Health Markers: a 4 Way Randomised Crossover Study

NCT05220059

Cardiovascular Diseases Endothelial Dysfunction Blood Pressure

UNKNOWN NA

Effects of a Brown Seaweed Tart Cherry Blend in Mild-moderate Hypertension

NCT06559982

Hypertension

NOT_YET_RECRUITING NA

Effects of Seaweed Extract on Mental Performance Following a High-carbohydrate Meal

NCT03328923

Cognitive Change

COMPLETED NA

Flavonoids, Blood Pressure and Blood Vessel Function

NCT01530893

Cardiovascular Disease Risk Reduction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

400mg capsule containing seaweed extract (treatment) Intervention: Dietary Supplement: Treatment capsule containing seaweed extract (treatment)

Group Type EXPERIMENTAL

Seaweed extract

Intervention Type DIETARY_SUPPLEMENT

Treatment capsule containing seaweed extract (treatment)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Seaweed extract

Treatment capsule containing seaweed extract (treatment)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Good general health
* Body Mass Index of 18-30 Kg/m2

Exclusion Criteria

* Inability to swallow capsules
* Smoking
* Alcohol intake of \>21 units/wk
* Blood pressure \> 150/90 mmHg
* Any dietary restrictions or weight reducing diet
* Vegetarian
* Heamoglobin levels\< 125 g/l for male, \< 110 g/l for female,
* Gamma GT levels \> 80 IU/l
* Cholesterol levels \> 6.5 mmol/l
* Myocardial infarction or stroke in the previous 12 months
* Gastrointestinal disease or chronic gastrointestinal disorders
* Reproductive disorder
* Blood-clotting disorder
* Metabolic disorders
* Lipid-modifying medication
* Blood clotting mdication
* Antibiotic medication in previous 3 months before study
* Lactation
* Pregnancy
* Females of childbearing potential and not using effective contraceptive precautions

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes